Ortho Clinical Diagnostics Holdings plc
OCDXDelisted May 27, 2022- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001828443
Ortho Clinical Diagnostics Holdings plc was delisted on May 27, 2022; its insiders filed their last Form 4 on Jun 1, 2022; 170 institutions reported holding it in 13F filings for Q1 2022, worth $4.38B in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 170
- Q1 2022, +8 vs. previous quarter
- 13F value
- $4.38B
- Reported value at the end of Q1 2022
- Superinvestors holding
- 0
- At the end of Q1 2022
Superinvestors holding OCDX, Q1 2022
No superinvestor reported holding OCDX at the end of Q1 2022.
Latest insider trades
Open-market purchases and sales by Ortho Clinical Diagnostics Holdings plc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 6, 2022 (view filing) | Apr 4 | 2 days | Schlesinger Michael A.EVP, GC and Secretary | SSaleOrdinary Shares, $0.00001 par value | −88.0K | $18.77 | −$1.65M | −50.1%87.6K after | |
| Jan 5, 2022 (view filing) | Jan 3 | 2 days | Smith Christopher MChairman and CEO | SSaleOrdinary Shares, $0.00001 par value | −100.0K | $21.10 | −$2.11M | −21.4%367.4K after | |
| Jan 5, 2022 (view filing) | Jan 3 | 2 days | Schlesinger Michael A.EVP, GC and Secretary | SSaleOrdinary Shares, $0.00001 par value | −130.0K | $21.09 | −$2.74M | −59.7%87.6K after | |
| Oct 19, 2021 (view filing) | Oct 15 | 4 days | Schlesinger Michael A.EVP, GC and Secretary | SSaleOrdinary Shares, $0.00001 par value | −75.5K | $19.73 | −$1.49M | −46.3%87.6K after | |
| Sep 16, 2021 (view filing)4:30 PM ET | Sep 14 | 2 days | TC Group Cayman Investment Holdings, L.P. and 8 others10% Owner | SSale | −25.3M | $16.80 | −$425.0M | −17.6%118.1M after | |
| Aug 18, 2021 (view filing) | Aug 16-18 | 2 days | Schlesinger Michael A.EVP, GC and Secretary | SSaleOrdinary Shares, $0.00001 par value | −45.0K | $20.13 | −$906.2K | −33.9%87.6K after | 2 lots |
| Aug 13, 2021 (view filing) | Aug 11-13 | 2 days | Schlesinger Michael A.EVP, GC and Secretary | SSaleOrdinary Shares, $0.00001 par value | −85.0K | $19.80 | −$1.68M | −49.2%87.6K after | 3 lots |
| Aug 4, 2021 (view filing) | Aug 2-4 | 2 days | Yates Robert CliftonDirector | SSaleOrdinary Shares, $0.00001 par value | −341.7K | $21.71 | −$7.42M | −98.5%5.20K after | 3 lots |
| Aug 4, 2021 (view filing) | Aug 2-4 | 2 days | Smith Christopher MChairman and CEO | SSaleOrdinary Shares, $0.00001 par value | −270.0K | $21.82 | −$5.89M | −42.4%367.4K after | 3 lots |
Top 10 13F holders, Q1 2022
The largest institutional positions in Ortho Clinical Diagnostics Holdings plc at the end of Q1 2022; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Carlyle Group Inc. | 118,106,000 | $2.20B | 26.36% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 19,489,153 | $363.7M | 0.04% | −492,505−2.5% | Reduced |
| Vanguard Group Inc | 11,047,197 | $206.1M | 0.00% | −31,527−0.3% | Reduced |
| BlackRock Inc. | 8,564,333 | $159.8M | 0.00% | −167,745−1.9% | Reduced |
| JPMorgan Chase & Co | 8,543,032 | $159.4M | 0.02% | +1,601,542+23.1% | Added |
| Versor Investments LP | 5,163,657 | $96.4M | 3.60% | +749,705+17.0% | Added |
| Shapiro Capital Management LLC | 4,592,531 | $85.7M | 1.80% | −1,355,300−22.8% | Reduced |
| Janus Henderson Group PLC | 4,476,193 | $83.5M | 0.04% | −3,592,340−44.5% | Reduced |
| Magnetar Financial LLC | 3,639,599 | $67.9M | 0.73% | +1,864,265+105.0% | Added |
| Lazard Asset Management LLC | 3,325,462 | $62.1M | 0.07% | −433,127−11.5% | Reduced |